Search

Your search keyword '"Kaidarova, Dilyara R."' showing total 7 results
Start Over "Kaidarova, Dilyara R."
7 results on '"Kaidarova, Dilyara R."'

4. Analysis of Delays in Breast Cancer Treatment and Late-Stage Diagnosis in Kazakhstan

Author

Chukmaitov, Askar S, Kaidarova, Dilyara R, Talaeyva, Shnar T, Sheppard, Vanessa B, Xu, Haiyong, Siangphoe, Uma, and Ettner, Susan L

Subjects
Delayed Diagnosis, Breast Neoplasms, Middle Aged, Prognosis, Kazakhstan, delays in treatment, Time-to-Treatment, Breast cancer, Life Expectancy, late-stage diagnosis, Humans, Female, Research Article, Aged, Follow-Up Studies, Mammography, Retrospective Studies
Abstract

Objective: Although Kazakhstan has made significant investments to improve health and life expectancy of its population, high cancer rates persist, with breast cancer being the most prevalent type. Factors contributing to delays in treatment and late staging for breast cancer patients were assessed. Methods: A retrospective follow-up study with registry data identified 4,248 breast cancer patients in sixteen regions of Kazakhstan in 2014. We used logistic regressions to estimate (i) associations of treatment delays with patient demographics and cancer center regions; and (ii) associations of late-stage (III and IV) cancer diagnosis with patient demographics and cancer center regions, with and without controlling for treatment delays. Results: Breast cancer patients treated in regions located further away from Almaty City had higher risks of treatment delays. However, the risks of late-stage cancer diagnosis were greater for patients treated in Almaty City and those with treatment delays. Conclusion: The main driver of delayed treatment is cancer center region. Residents of Almaty City, a major urban area of Kazakhstan, may have a better access to a tertiary cancer center, resulting in less treatment delays. Referrals of sicker patients from neighboring regions to Almaty City for cancer treatment is likely to increase risks of late-stage diagnosis. New or upgraded cancer centers may reduce treatment delays, but their case-mix is likely to increase.

Published
2018

6. Immune polychemotherapy regimen choice in B-cell non-Hodgkin lymphoma of high and low malignancy based on the identification of the mutational c-myc and BCL 2 genes.

Author

Kaidarova, Dilyara R., Karakulov, Raiymkul K., Gabbasova, Saule T., Karazhanova, Meruert K., and Lyubko, Svetlana A.

Subjects
*BCL genes, *NON-Hodgkin's lymphoma, *COMBINATION drug therapy, *STEM cell transplantation, *GENE expression profiling, *SOMATIC mutation
Abstract

Introduction: The relevance of research is conditioned by the study of the gene expression profile for the identification of molecular subgroups of non-Hodgkin B-cell lymphomas (NHBCLs) in haematology. Aim: The aim of this research was to study the gene expression profile with the identification of molecular subgroups in patients with NHBCLs for personalised treatment. Material and methods: This paper is aimed at analysing the frequency and role of expression of c-myc, B-cell lymphoma 2 (BCL 2) proteins and the Ki 67 proliferative index in patients with NHBCLs and conducting personalised therapy to improve the immediate effectiveness and immediate treatment results. Results and discussion: The paper presents the results of the use of high-dose polychemotherapy (PCT) in 9 patients out of 80 with NHBCL during coexpression of the c-myc, BCL 2 mutational gene and with high values of the Ki 67 proliferative index. High-dose chemotherapy (HDCT) was performed according to the R+HyperCVAD scheme (6 courses) and hematopoietic stem cell (HSC) autotransplantation improved the immediate effectiveness of therapy, with a complete remission rate of 80% and an event-free survival of 28 months. Conclusions: The study of molecular genetic characteristics in 80 patients with NHBCLs revealed co-expression of the c-myc and BCL 2 mutational gene in 9 out of 80 patients, and they differed in the aggressive course, 'poor' response to therapy, which predetermined the use of high-dose PCT with transplantation of autologous stem cells. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results